Decision-making in drug development

  • Dates: 12 Dec, 2018
  • How to find us: Servier 50 Rue Carnot, F- 92284 Suresnes France
Taking decisions during the development of a new drug requires combining many and varying pieces of information. The interconnections between them are often only partially known, reflecting the complexity of the context in which drugs are evaluated and the cognitive load required for health care decisions. Decision-makers need quantitative tools to support informed decisions, with transparent processes that synthesize the whole available information in order to evaluate the success associated to different options.

This meeting aims to bring together statisticians from the pharmaceutical industry and academia to hear about recent advances in statistical methods for quantitative decision-making in drug development.

Confirmed speakers include:

Anthony O'Hagan
University of Sheffield 
Introduction to decision-making
Juan Abellan
GSK
Prior elicitation to support quantitative decision-making
Paul Frewer
Astra Zeneca
Decision Making in Early Clinical Development: The framework used within AstraZeneca
Maria Costa
Novartis
Benefit-Risk Assessment in Drug Development
Nigel Stallard
University of Warwick
Decision-making in phase II/III trials using early endpoint data
Tom Parke
Berry Consultants
Using simulations to optimize drug development decision-making

Poster Session - Call for Abstracts:

If you wish to present a poster, please send an abstract to Gaëlle Saint-Hilary (gsainthilary@gmail.com) by October 31st 2018. The notification of acceptance will be provided by November 9th 2018.

For more details and to view the flyer, please click here.
Add event to: ICal Outlook Google Calendar